InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update
06 août 2024 08h09 HE
|
InspireMD, Inc.
- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any...
InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment
05 août 2024 07h00 HE
|
InspireMD, Inc.
CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE...
InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th
30 juil. 2024 07h00 HE
|
InspireMD, Inc.
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel, and MIAMI, July 30, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention...
InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million
01 juil. 2024 07h00 HE
|
InspireMD, Inc.
Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall...
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
28 mai 2024 08h53 HE
|
InspireMD, Inc.
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a...
InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 07h00 HE
|
InspireMD, Inc.
- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS...
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th
07 mai 2024 07h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery...
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 08h59 HE
|
InspireMD, Inc.
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
26 mars 2024 07h00 HE
|
InspireMD, Inc.
TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
06 mars 2024 07h00 HE
|
InspireMD, Inc.
- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device...